Myhibbin in Pakistan

Myhibbin - overview

Myhibbin (nintedanib class) is manufactured by Boehringer Ingelheim (verify) and indicated for prophylaxis of organ rejection in adult and pediatric recipients of allogeneic kidney, heart, or liver transplants. It is an oral suspension, ready-to-use (no reconstitution) approved by the US FDA in 2024 and may be accessible to patients in Pakistan through a Named Patient Program or personal-import pathway.

Access in Pakistan

Pakistan's DRAP permits personal-use import of unregistered specialty drugs; documentation-heavy process.

How Reserve Meds coordinates access in Pakistan

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Pakistan-specific eligibility.
3. Treating physician in Pakistan issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Myhibbin from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Pakistan.

Typical timeline for Pakistan

End-to-end, most requests are completed in 2-6 weeks. Pakistan's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Pakistan ask

• Is the pathway legal in Pakistan? Yes - it operates under Pakistan's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Pakistan able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Myhibbin in Pakistan

Join the Myhibbin waitlist